Over half of all states permit the use of medical cannabis for certain qualifying conditions, even though it remains illegal as a Schedule 1 controlled substance under federal law. What are the potential costs and implications on the commercial insurance and Medicaid markets if states were to mandate the coverage of medical cannabis for patients enrolled in either of these two markets?
This report was commissioned by Greenwich Biosciences, Inc.